1. Introduction {#sec0001}
===============

Fluoroquinolones are among the most widely used antibiotics [@bib0001] and they are commonly used for the treatment of respiratory tract infections. Because fluoroquinolones show bactericidal activity against Mycobacterium tuberculosis complex, there is concern that their use can delay the diagnosis of tuberculosis. The literature on this topic has yielded variable results regarding this association. The International Standards for TB Care recommend against the use of fluoroquinolones in adults with suspected tuberculosis [@bib0002]; however, these recommendations may not be followed consistently, as shown in recent simulated patient studies from India [@bib0003], [@bib0004]. Moreover, both the IDSA/ATS as well as the European guidelines for the treatment of community-acquired pneumonia include respiratory fluoroquinolones (moxifloxacin, gemifloxacin or levofloxacin) as a first-line treatment option for patient with co-morbidities [@bib0005], [@bib0006]. A previous meta-analysis on the topic was published in 2011 [@bib0007]; since then, new studies have been published, warranting an updated systematic review.

2. Methods {#sec0002}
==========

We conducted a systematic review and meta-analysis to assess whether empiric treatment with fluoroquinolones delays the diagnosis and treatment of tuberculosis in patients with lower respiratory tract infections.

The primary objective was to assess the delay in days in the diagnosis and treatment of tuberculosis, among patients who received fluoroquinolones, compared to those who were treated with non-fluoroquinolone antibiotics. We aimed to limit selection bias by restricting the comparison to patients who had received non-fluoroquinolone antibiotics only instead of patients who had not received any antibiotics. This was done to ensure comparability of both groups as patients may be subject to differential prescribing patterns and medical investigation procedures depending on their pre-test probability of tuberculo-sis as determined by their treating physician.

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [@bib0008] for the planning and execution of this study. With the assistance of a medical librarian (GG), we performed a literature search of seven databases (PubMed, Embase, CINAHL, Cochrane Library, Web of Science, Biosis and Global health) with no language restrictions through to August 8th 2016. We excluded case series of less than 10 patients, as well as articles for which either the full text or information on diagnostic delay was not available.

The titles and abstracts of identified articles were screened independently by two reviewers (CH and LP) based on a prespecified protocol. Publications identified as relevant by at least one reviewer were searched for full-text appraisal. Two reviewers completed full-text evaluations, selected articles, and extracted the data independently. Study quality assessment was performed by two reviewers using a tool ([Table 1](#tbl0001){ref-type="table"}) developed at McGill University for TB diagnostic delay studies [@bib0009]. Disagreement was resolved by consensus. Study authors were contacted in case of ambiguity or missing data, and for clarification of study methodology.Table 1Study quality assessment of the ten studies included in the systematic review.Table 1Main author, publication year (reference)Patient samplingDefinition of delay[\*](#tb1fn1){ref-type="table-fn"}Definition of confirmation of TB diagnosisDealing with confoundingConsecutive or random (low risk of bias)Not consecutive or random (high risk of bias)Not described (no description)Clearly stated delay definition (low risk of bias)Stated but delay definition unclear (high risk of bias)No definition (no description)Clearly stated method of Dx of TB (low risk of bias)No definition (no description)Potential confounders identified and adjusted for (low risk of bias)Potential confounders not identified, or identified but not adjusted for (high risk of bias)Rush 2016 [@bib0011]All cases includedClearly statedCulture or PCRConfounders identified but not adjusted forWang 2015 [@bib0012]All cases includedClearly stated50--60% by culture or NAAT; rest by ICD codeConfounders identified but not adjusted forKim 2013 [@bib0013]Not describedClearly statedCultureConfounders identified but not adjusted forWang 2011 [@bib0014]All cases includedClearly statedCultureConfounders identified but not adjusted forJeon 2011 [@bib0015]Not describedClearly statedCultureConfounders identified but not adjusted forWang 2006 [@bib0016]All cases includedClearly statedCultureYes, adjusted for smear statusSierros 2006 [@bib0017]All cases included; some cases later excluded re: availability of medical records or resultsClearly statedCultureYes, adjusted for smear statusGolub 2005 [@bib0018]All cases eligible but sampling strategy not describedClearly statedCultureConfounders identified but not adjusted forYoon 2005 [@bib0019]Not describedClearly statedCultureConfounders identified but not adjusted forDooley 2002 [@bib0020]All cases includedClearly statedCultureYes, adjusted for smear status[^1]

The data were analyzed with the use of Stata version 12.1 (Statacorp, Texas, USA). The main outcome for the analysis was delay in time of presentation to time of start of anti-tuberculosis therapy in the fluoroquinolone group compared to the non-fluoroquinolone group. The threshold for statistical significance was set at a p-value of 0.05. First, an unweighted average of the estimate of delay was calculated for all studies. Second, for the studies for which the estimate was available as a mean with standard deviation, a weighted average using a random effects meta-analysis model was estimated.

3. Results {#sec0003}
==========

A total of 3983 citations were identified from the literature search; of these, 17 articles were selected for full-text review. A total of 10 studies were retained for the synthesis ([Fig. 1](#fig0001){ref-type="fig"}). These included 7 retrospective cohort studies and 3 case-control studies. Only one of the 10 studies was from a high TB burden country, South Africa. A total of 18,179 patients were included in the 10 studies. The proportion of male participants in the studies ranged from 54 to 99%; HIV seroprevalence ranged from 0 to 58%. The most commonly used fluoroquinolones were levofloxacin, gemifloxacin, moxifloxacin and ciprofloxacin.Fig. 1PRISMA flow diagram.Fig 1

For most studies, study quality was considered fair for the definition of delay and for the definition of confirmation of diagnosis ([Table 1](#tbl0001){ref-type="table"}). There was limited information available regarding patient sampling methods, as well as strategies to deal with potential confounders. In addition, most studies did not adjust their estimates of diagnostic delay by potential confounders.

The mean difference in delay in time of presentation to time of start of anti-tuberculosis therapy in the fluoroquinolone group compared to the non-fluoroquinolone group varied from 0d to 28d across the 10 studies ([Table 2](#tbl0002){ref-type="table"}). The unweighted average of difference in delay was 12.9 days (95% CI 6.1--19.7). The estimate of delay was available as a mean with standard deviation for five of the ten studies. When the differences for these studies were pooled using a random effects model, the weighted estimate was 10.9 days (95% CI 4.2--17.6). When stratified by acid-fast smear status, the delay was consistently greater in the smear-negative group. Based on one study, there was suggestion of a proportional increase in the diagnostic delay based on the duration of fluoroquinolone exposure (18.3 days in the one-day exposure group; 23.1 days in the ≥ 5 day group). However, there was overlap in the confidence intervals around these estimates. Heterogeneity in the study design and outcomes was present although this was not statistically evaluated.Table 2Baseline characteristics of the ten studies included in the systematic review.Table 2Main author, publication year (reference)Setting, countryStudy designFluoroquinolone used (number of patients)Antibiotics used in the non-fluoroquinolone groupDuration of fluoroquinolone exposure (mean (SD) or median (IQR) in days)Time from presentation to initiation of anti-TB treatment (mean (SD) or median (IQR) in days)Number of participantsAll patientsDifference between FQ and non-FQ groups (days)AFB smear positiveAFB smear negativeRush 2016 [@bib0011]Inpatients, CanadaRetrospective cohortMoxi (9)N/AN/AFQ914 (IQR 3--33)12.0N/AN/ANon-FQ332 (IQR 1--5)Wang 2015 [@bib0012]Inpatients and outpatients, TaiwanRetrospective cohortLevo (908), moxi (716), cipro (402), oflox (25)Penicillins, cephalosporins, carbapenems, macrolides≥7FQ205163.0 (47.1)13.6N/AN/ANon-FQ14,63249.4 (47.6)Kim 2013 [@bib0013]Inpatients, South KoreaCase-controlMoxi (10), levo (4), cipro (2)Cephalosporins, macrolides, beta-lactam/beta-lactamase inhibitor14 (IQR 7--37)FQ1635 (IQR 14--72)28.0N/AN/ANon-FQ327 (IQR 3--63)Wang 2011 [@bib0014]Inpatients and outpatients, CanadaRetrospective cohortCipro, Levo, Moxi (N/A)Macrolides, penicillins, sulfonamide, cephalosporinsN/AFQ3653.2 (53.6)0N/AN/ANon-FQ25853.4 (46.7)Jeon 2011 [@bib0015]Inpatients and outpatients, South AfricaRetrospective cohortCipro, oflox (N/A)N/A≥5FQ9023.1 (28.9)3.3N/AN/ANon-FQ51119.8 (30.1)Wang 2006 [@bib0016]Inpatients, TaiwanRetrospective cohortCipro (42), levo (21), moxi (16)N/A9.5 (6.0)FQ7945.4 (37.3)17.715 (IQR 8--175)42 (IQR 6--233)Non-FQ21827.7 (30.5)6 (IQR 0--105)27 (IQR 0--198)Sierros 2006 [@bib0017]Inpatients and outpatients, USARetrospective cohortLevo (17), cipro (2), gati (1)Beta-lactam/beta-lactamase inhibitor, macrolides3 (no IQR)FQ20N/A14 (smear-positive)32 (no IQR)46 (no IQR)Non-FQ48N/A18 (no IQR)34.5 (no IQR)Golub 2005 [@bib0018]Inpatients and outpatients, USACase-controlN/AMacrolides, cephalosporins, amoxicillin, TMP-SMX, clindamycin, vancomycinN/AFQ4539.0 (no IQR)0.5N/AN/ANon-FQ4038.5 (no IQR)Yoon 2005 [@bib0019]Inpatients, South KoreaCase-controlLevo (7), cipro (2)Cephalosporins, macrolides, beta-lactam/beta-lactamase inhibitor, aminoglycosides14.2 (8.3)FQ943.1 (40.0)24.4N/AN/ANon-FQ1918.7 (16.9)Dooley 2002 [@bib0020]Inpatients and outpatients, USARetrospective cohortLevo (11), trova (2), gati (1), cipro (1), cipro then trova (1)Cephalosporins, macrolides, TMP-SMXN/AFQ1621 (IQR 5--32)169 (no IQR)24 (no IQR)Non-FQ175 (IQR 1--16)1 (no IQR)16 (no IQR)[^2]

4. Discussion {#sec0004}
=============

A previous systematic review and meta-analysis on this topic was published in 2011 [@bib0007], and reported a mean diagnostic delay of 19.0 days (95% CI 10.9--27.2). This systematic review serves as an update with the addition of six new studies. Our mean diagnostic delay of 12.9 days (95% CI 6.1--19.7) also supports fluoroquinolones contributing to the diagnostic delay of tuberculosis. However, heterogeneity across studies suggests that this pooled estimate must be interpreted with caution.

The most plausible mechanism to explain this observed delay relates to the bactericidal activity of fluoroquinolones against *Mycobacterium tuberculosis* [@bib0017], thus delaying the diagnosis of tuberculosis. Moreover, fluoroquinolones may transiently improve the respiratory symptoms of tuberculosis, also contributing to delay. In vitro experiments have demonstrated that the bactericidal power of moxifloxacin and levofloxacin against *Mycobacterium tuberculosis* far outweighs that of ciprofloxacin [@bib0010].

The potent bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis has made it a candidate of choice for the new short-course studied regimens, including PAMZ (pretomanid, moxifloxacin and pyrazinamide; currently in phase (3) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide; currently in advanced phase (2). As such, there is a compelling drive to protect quinolones from possible emerging resistance, an outcome this study did not assess.

The suggestion of a proportional relationship between the duration of fluoroquinolone exposure and delay in tuberculosis diagnosis is interesting and deserves further attention. The only study [@bib0015] that reported on the diagnostic delay of tuberculosis as a function of time categorized fluoroquinolone use by 1 day, 2--4 days and ≥ 5 days. There was a trend toward longer diagnostic delay in the group treated for ≥ 5 days compared to the two other groups; however, the confidence intervals overlapped around these estimates. This suggests that there may be a benefit in stopping the fluoroquinolone at the beginning of treatment if one thinks of tuberculosis as a diagnostic possibility even after the start of empiric antibacterial treatment.

Our study presents certain limitations. In particular, there was important variation in study settings, patient populations and in the definitions of delay used for the studies. Generalizability may also be limited given that only one study was from a high TB incidence country. Most studies reported delay as defined by the time to initiation of treatment; as such, the extra time between time of diagnosis and time of initiation of treatment is not adequately captured. In addition, data were lacking on variables such as delay in obtaining a diagnostic procedure (bronchoscopy or sputum induction), and on potential confounders (e.g. smear status, previous tuberculosis). Sufficient information was not available to stratify the meta-analysis diagnostic delay estimate by HIV status.

Furthermore, we attempted to limit bias by restricting the comparison to patients who had received antibiotics only. Unfortunately, this restriction was not possible for two studies [@bib0017], [@bib0020] where the groups were mixed with those having received non-fluoroquinolone antibiotics, and those not having received antibiotics. This information was not available for one study [@bib0015]. We recognize that physician behavior may play an important role in accelerating or not the investigations for a patient depending on the underlying suspicion of tuberculosis.

Finally, the study with the largest number of patients did not include culture diagnosis as necessary for inclusion in the study; this may have decreased power to detect a significant difference between the fluoroquinolone and non-fluoroquinolone groups. In addition, the approximation that medians and means were similar may not have been valid in the context of non-normally distributed data.

5. Conclusion {#sec0005}
=============

Although the available literature has several limitations and study results are heterogeneous, the evidence suggests that the use of fluoroquinolones in patients with respiratory infections might delay the diagnosis of active pulmonary TB by nearly 2 weeks. Consistent with the International Standards for TB Care, their use should be avoided when tuberculosis is suspected.
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[^1]: The definition of delay varied between the studies: time of sputum collection to initiation of anti-TB medications: 2 studies; presentation to initiation of anti-TB medications: 5 studies; time of initiation of antibiotics to initiation of anti-TB medications: 2 studies; time of sputum collection to culture growth: 1 study

[^2]: SD: standard deviation; IQR: inter-quartile range; moxi: moxifloxacin; N/A: not available; FQ: fluoroquinolone; levo: levofloxacin; gati: gatifloxacin; trova: trovafloxacin; cipro: ciprofloxacin; gemi: gemifloxacin; oflox: ofloxacin; USA: United States of America; TMP-SMX: trimethoprim-sulfamethoxazole
